=Cynosure (CYNO) to be acquired by Hologic (HOLX) for $66/share

• Hologic (HOLX) announced a $1.65 billion plan to acquire body-sculpting firm Cynosure (CYNO) early Tuesday, a day after Allergan (AGN) said it would pay $2.5 billion for fat-freezing Zeltiq (ZLTQ).
• Hologic, a leader in women's health, sees Cynosure as its ticket to the medical aesthetics market. Cynosure's portfolio includes more than 20 products in body sculpting, hair removal and skin revitalization.
• Cynosure goes after the obstetrics and gynecological markets to make its sales — about 60% of its revenue is derived from that market vs. traditional plastic surgery and dermatology. Hologic has a strong presence in the OB/GYN market.
• The medical aesthetics market is worth more than $2 billion annually across the globe, Hologic said. On Monday, Allergan put a $4 billion price tag on body sculpting alone when it announced its plan to buy Zeltiq, which uses a technique to freeze fat cells.